drugset / Trial / NCT05611671
A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a Phase 2b randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of three active dose regimens of MORF-057 in adult patients with moderately to severely active Ulcerative Colitis (UC).
Timeline
- Start
- 2022-11-21
- Primary completion
- 2024-11-28
- Completion
- 2026-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY4268989 | Unknown | 100 mg | Oral |
| Subject | LY4268989 | Unknown | 200 mg | Oral |